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 Angiogenic factors play a major role in tumor growth 
and metastasis. Vascular endothelial growth factor (VEGF)-
D is a ligand for VEGF receptor-3 (VEGFR-3/Flt-4), which 
mainly expressed on the lymphatic endothelium. Recent ex-
perimental studies have shown that VEGF-D induces tumor 
lymphangiogenesis and promote metastatic spread of tumor 
cells via lymphatic vessels. However, the contribution of VEGF-
D to lymph node metastasis in human colorectal cancer is less 
understood. We therefore examined VEGF-D and VEGFR-3 
expression in patients with colorectal cancer. Sections of 
formalin-fixed and paraffin-embedded specimens from 76 
colorectal cancers were immunohistochemically stained for 
VEGF-D and VEGFR-3. Staining for VEGF-D was positive in 
the cytoplasm of tumor cells in 43 of 76 examined tumors 
(56.6%). Staining for VEGFR-3 was positive in endothelial cells 
in 38 (50.0%) tumors. Univariate analysis showed that both 
VEGF-D and VEGFR-3 expressions correlated significantly 
with lymph node metastasis, histological type and depth of 
tumor invasion. However, logistic regression analysis indi-
cated that VEGF-D expression, but not that of VEGFR-3, 
was an independent predictor for lymph node metastasis. 
Our data suggest that VEGF-D plays an important role in 
lymph node metastasis in colorectal cancer. 
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Introduction
 The capacity of tumor cells to induce angiogenesis 
and lymphangiogenesis may regulate the probability 
of hematogenous or lymphatic metastasis. Lymph-
angiogenesis is controlled, in part, by members of the 
vascular endothelial growth factor (VEGF) family, i.e., 
VEGF-C, and VEGF-D, and their receptor on lymphatic 
endothelium, VEGFR-31,2'. VEGF-C was initially identi-
fied as a ligand for VEGFR-33'. Because expression of 
VEGFR-3 is mainly restricted to the lymphatic endo-
thelium, the major function of VEGF-C appears to be 
the regulation of lymphatic vessel growth"'). VEGF-C 
has been shown to regulate the growth of lymphatic 
vessels in various experimental models' 6 
 VEGF-D is the most recently discovered member of 
the VEGF family. It was isolated as a fos-inducible 
factor from mouse skin fibroblasts and the mature 
form shares about 60% amino acid sequence identity 
with VEGF-C 2'' ) . In addition to their sequence identity, 
VEGF-C and VEGF-D are thought to have similar bio-
logical functions because they can bond to common 
receptors. These secreted growth factors are synthe-
sized as propeptides that are activated by proteolysis 
to form high-affinity ligands that activate VEGFR-3 
and stimulate lymphangiogenesis 8'') . In experimental 
mouse tumor model, it is reported that VEGF-C and 
VEGF-D can induce tumor lymphangiogenesis and di-
rect metastasis to the lymphatic vessels and lymph 
nodes'"'). In human, recent studies indicated that VEGF-
D is upregulated in malignant melanoma"', inflamma-
tory breast carcinoma"), and colorectal cancer"), sug-
gesting that VEGF-D expression is associated with 
lymph node metastasis in various human malignan-
cies. 
 In the present study, we examined the expression of 
VEGF-D and VEGFR-3 in colorectal cancer and inves-
tigated their relationship to lymph node metastasis, 
one of the most important prognostic factors in colo-
rectal cancer.
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Material and Methods
Patients
 Seventy-six tissue samples were obtained from pa-
tients with colorectal cancer who had been operated 
between 1997 and 1998 at the Division of Surgical 
Oncology, Department of Translational Medical Science, 
Nagasaki University Graduate School of Biomedical 
Sciences. The group consisted of 52 males and 24 fe-
males, with a mean age at the time of surgery of 62. 
5±12.0 years (± SD, range: 29-88 years). None had re-
ceived chemotherapy or radiotherapy before surgery. 
Forty tumors were localized in the colon and 36 tu-
mors were in the rectum. Seventy-three patients un-
derwent curative operation. The criteria of the American 
Joint Committee on Cancer Classification and stage 
grouping was used to classify tumors i61. The 76 pa-
tients included 1 patient with stage 0, 12 with stage 
I, 30 with stage II, 22 with stage III, and 11 with stage IV 
cancer. Eight tumors were classified as 'well-differentiated 
adenocarcinoma', 61 tumors as 'moderately-differentiated 
adenocarcinoma', 5 tumors as 'poorly-differentiated 
adenocarcinoma', and 2 tumors as 'mucinous carci-
noma'. A written informed consent was obtained from 
each patient for use in the present study.
Immunohistochemistry for VEGF-D and VEGFR-3
 The mouse monoclonal anti-VEGF-D antibody pur-
chased from R&D systems, Inc (Minneapolis, MN) was 
used for staining at a concentration of 10 u g/ml. The 
rabbit polyclonal anti-VEGFR-3 antibody purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) 
was used at 2 u g/ml. Immunohistochemical staining 
was performed as follows. Serial sections (3-4-gm 
thick) from formalin-fixed, paraffin-embedded tissue 
blocks were deparaffinized and then heated in a mi-
crowave oven in 10 mM citrate buffer, pH 6.0, for 10 
min. The sections were then treated in methanol con-
taining 3% hydrogen peroxide for 10 min at room 
temperature. They were subsequently washed in dis-
tilled water, rinsed for phosphate buffered saline 
(PBS), and treated with nonspecific staining blocking 
reagent containing 0.25% casein (DAKO, Glostrup, 
Denmark) for 10 min at room temperature. The slides 
were then incubated overnight at 4°C in a humidified 
chamber with anti-VEGF-D or anti-VEGFR-3 antibody 
diluted in PBS with 1 % bovine serum albumin (BSA). 
After washing the specimens with PBS, the slides 
were incubated with biotinylated anti-mouse or anti-
rabbit IgG for 30 min at room temperature. After 
three washes in PBS, the sections were incubated with
streptavidin-peroxidase reagent for 30 min at room 
temperature. VEGF-D antigen and VEGFR-3 antigen were 
developed by incubating the slides in diaminobenzidine 
(DAKO) solution containing 0.06 mM diaminobenzidine 
and 2 mM hydrogen peroxide in 0.05% PBS (pH 7.6) for 
5 min. Sections were counterstained with hematoxylin, 
dehydrated with alcohol and xylene, and mounted in 
a routine fashion. Negative controls were performed in 
all cases by omitting the first antibody.
Assessment of immunoreactivity
 VEGF-D expression in the tumors was measured by 
assessing the percentage of positively stained cells. 
Tumors were classified into three categories according 
to the extent of staining: (+), over 20% of tumor cells 
were stained; (± ), less than 20% of tumor cells were 
stained, and (- ), completely negative. (-) and (±) 
were classified as negative for VEGF-D, (+) was classi-
fied as positive for VEGF-D. For VEGFR-3 expression 
in endothelial cells, we scored the tumors as positive 
for VEGFR-3 when VEGFR-3 positive vessels were 
found at the tumor periphery.
Statistical analysis
 Patients were divided into two groups based on the 
median age (62 years). The statistical significance among 
VEGF-D, VEGFR-3 expressions, and clinicopathological 
features was evaluated using chi-square test. Backward 
stepwise logistic regression model was used for multi-
variate adjustments for all covariates simultaneously. 
All statistical. analyses -.described in this study were 
conducted using STATISTICATM software (StatSoft, Inc. 
Tulsa, OK).
Results
VEGF-D expression in colorectal cancer
 VEGF-D was detected in the cytoplasm of tumor 
cells, and no expression was observed in the nucleus 
(Figure 1). Expression of VEGF-D tended to be local-
ized to the deep layer of the tumor. In specimens of 
normal colonic mucosa, no VEGF-D expression was 
observed. Among the 76 tumors, 43 (56.6%) were posi-
tive for VEGF-D expression. The relationship between 
VEGF-D expression and clinicopathological features is 
summarized in Table 1. VEGF-D expression was sig-
nificantly associated with histological type and depth 
of invasion (p=0.03 and <0.01, respectively). There was 
no correlation between VEGF-D expression and
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Table 1. VEGF-D and VEGFR-3 expressions, and clinicopathological 
features.
                      VEGF-D expression VEGFR-3 expression 
                   Negative Positive P value Negative Positive P value 
Age 0.04 0.65 
 <62 years 19 15 17 19 
 >_62 years 14 28 21 19 
Gender 0.77 0.32 
 Male 22 30 28 24 
 Female 11 13 10 14 
Histological type 0.03 <0.01 
 well 5 3 8 0 
 moderate 28 33 28 33 
 poor, mucinous 0 7 2 5 
Depth of invasion <0.01 0.02 
 Tis, T1, T2 13 3 12 4 
 T3, T4 20 40 26 34 
Lymphatic involvement 0.38 0.38 
 negative 8 7 9 6 
 positive 25 36 29 32 
Venous involvement 0.86 0.64 
 negative 17 23 19 21 
 positive 16 20 19 17 
Lymph node metastasis <0.01 0.02 
 negative 27 17 27 17 
 positive 6 26 11 21 
Liver metastasis 0.38 0.77 
 negative 28 33 31 30 
 positive 5 10 7 8
well, well-differentiated adenocarcinoma; moderate, moderately-differentiated 
adenocarcinomas; poor, poorly-differentiated adenocarcinoma; mucinous, mucinous 
carcinoma.
Table 2. Logistic regression analysis of VEGF-D with respect 
to lymph node metastasis.
Figure 1. Immunohistochemical staining for VEGF-D in colon 
cancer. 
 Note the positive immunoreactivity for VEGF-D predomi-
nantly in the cytoplasm of tumor cells. Magnification: (a), 
x100; (b), x400.
gender, lymphatic involvement, venous involvement, 
or liver metastasis. The positive expression of VEGF-D 
was significantly higher in tumors with lymph node 
metastasis than in those without lymph node metasta-
sis (Table 1). Multivariate analysis revealed that VEGF-
D expression in tumor cells is an independent factor 
influencing lymph node metastasis (Table 2).
VEGFR-3 expression in colorectal cancer
 VEGFR-3 was detected in a subset of vessels, which 
were typically thin-walled and devoid of red blood 
cells (Figure 2). Thirty-eight of 76 tumors (50%) were 
positive for VEGFR-3 expression in endothelial cells. 
Although VEGFR-3 was detected in the cytoplasm of 
tumor cells with a staining pattern similar to that of 
VEGF-D (49 of 76 tumors, 64.4%), in this study we 
evaluated VEGFR-3 only in endothelial cells. Like
                 Odds ratio (95% CI) P value 
Histological type 
  well 1 
  moderate 1.31 (0.09 -19.08) 0.84 
   poor, mucinous 8.81 (0.23 - 338.58) 0.23 
Depth of invasion 
  Tis, T1, T2 1 
  T3, T4 1.90 (0.31 -11.71) 0.48 
Venous involvement 
  negative 1 
  positive 0.64 (0.18 - 2.28) 0.48 
Lymphatic involvement 
  negative 1 
  positive 24.31 (1.80 - 328.34) 0.015 
VEGF-D expression 
  negative 1 
  positive 5.31 (1.56-18.09) <0.01
CI, confidence interval. Other abbreviations as in Table 1.
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Table 3. Logistic regression analysis of VEGFR-3 with re-
spect to lymph node metastasis.
                 Odds ratio (95% CI) P value 
Histological type 
  well 1 
   moderate 0.89 (0.07 - 11.83) 0.92 
   poor, mucinous 9.28 (0.26 - 335.62) 0.22 
Depth of invasion 
   Tis, T1, T2 1 
   T3, T4 2.37 (0.41 -13.39) 0.32 
Venous involvement 
   negative 1 
   positive 0.64 (0.19 - 2.20) 0.48 
Lymphatic involvement 
   negative 1 
   positive 22.01 (1.67 - 290.05) 0.02 
VEGFR-3 expression 
   negative 1 
   positive 2.26 (0.70 - 7.34) 0.16
Abbreviations as in Tables 1 and 2.
Table 4. Relationship between VEGF-D expression and 
VEGFR-3 expression.
Figure 2. Immunohistochemical staining for VEGFR-3 in 
colon cancer. 
Note the positive immunoreactivity for VEGFR-3 in the en-
dothelium of vessels. Magnification: (a), x100; (b), x400.
VEGF-D, VEGFR-3 expression was significantly associ-
ated with histological type and depth of invasion (p < 
0.01 and p < 0.02, respectively). VEGFR-3 expression was 
significantly higher in tumors with lymph node me-
tastasis than in those without lymph node metastasis 
(Table 1). However, multivariate analysis revealed that 
VEGFR-3 expression was not an independent factor 
influencing lymph node metastasis (Table 3). VEGFR-3 
expression in endothelial cells was significantly associ-
ated with VEGF-D expression in tumor cells (Table 4).
Discussion
                    VEGFR-3 expression 
VEGF-D expression 
                Negative Positive P value 
Negative 25 8 <0.01 
Positive 13 30
 The VEGF family consists of VEGF-A, -B, -C, -D, and 
-E as well as placenta growth factor"' . The founding 
member, VEGF-A, plays essential roles in vasculogenesis 
and angiogenesis'$'. Although its crucial role in tumor 
angiogenesis and hematogenous metastasis has been 
documented in a variety of cancers"', little is known
about the physiological and pathological roles of other 
family members. Recent experimental studies with 
VEGF-C and VEGF-D have shown that they can in-
duce tumor lymphangiogenesis. However, few studies 
assessed the relevance of VEGF-D to lymph node me-
tastasis in human malignancies. VEGF-D activates 
VEGFR-2 (KDR/Flk-1) and VEGFR-3220', both of which 
are essential for vascular development"-"'. VEGFR-2 is 
expressed on vascular endothelial cells"' and VEGFR-3 
is mainly expressed in the endothelium of lymphatic 
vessels''. A recent study indicated that VEGF-D can 
stimulate both angiogenesis and lymphangiogenesis12'. 
However, another study showed that VEGF-D binds 
only to VEGFR-3 and induces only lymphangiogenesis 
in mouse tumor models''. 
 In the present study, VEGF-D was highly expressed
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in primary tumors of colorectal cancer with lymph 
node metastasis. On the other hand, the expression of 
VEGF-D was not related to hematogenous metastasis, 
such as liver metastasis or venous involvement. Recent 
studies demonstrated that VEGF-D is proteolytically 
processed in a manner similar to VEGF-C8'". It exists 
in numerous forms, as some molecules are completely 
processed, whereas others are partially processed or 
remain unprocessed". There is evidence indicating 
that the unprocessed or partially processed VEGF-Ds 
are capable of binding VEGFR-3, albeit with low affin-
ity, but fully proteolytic cleavage is necessary to gen-
erate the mature form that binds VEGFR-2 as well. 
These data suggest the possibility that the angiogenic 
versus lymphangiogenic responses to VEGF-D may de-
pend on, at least in part, the degree of proteolytic 
processing of this growth factor in different tumor en-
vironment, and that in colorectal cancer VEGF-D does 
not act as an angiogenic factor, but plays a role in the 
development of lymphatic vessels thereby promoting 
only lymphatic metastasis. Although the protease re-
sponsible for the processing is yet to be determined, 
we speculate that in colorectal cancer the protease is 
not expressed enough to generate fully processed 
VEGF-D. 
 Our results also showed a significant correlation be-
tween expression of VEGF-D and depth of tumor inva-
sion. That VEGF-D tended to be expressed in the deep 
layers of tumors suggests the increased potential of 
lymphangiogenesis following growth of such tumors, 
or reflects the malignant potential of tumor invasion. 
 Several studies have examined the relationship be 
tween VEGF-D and human malignancies '3,14,23,24>, Although 
recent studies have examined the expression of VEGF-
D in colorectal cancer, the role of this factor in lymph 
node metastasis is still controversial. White et al. 15) 
studied 84 patients with colorectal cancer and used 
univariate analysis to conclude that the expression of 
VEGF-D correlated with lymph node metastasis. On 
the other hand, George et al.25) reported that there was 
no correlation between VEGF-D expression and lymph 
node metastasis in 70 patients with colorectal cancer. 
Our results were consistent with the former study. To 
our knowledge, the present study is the first report to 
indicate that VEGF-D expression is an independent 
predictor of lymph node metastasis in colorectal can-
cer using multivariate analysis. 
 In the same population of patients, we examined the 
expression of VEGFR-3. VEGFR-3 expression was sig-
nificantly associated with tumor histological type and 
with depth of invasion. Furthermore, VEGFR-3 expres-
sion was significantly associated with VEGF-D expres-
sion, suggesting that the co-expression of VEGF-D and
VEGFR-3 may play an important role in tumor lymph-
angiogenesis. However, multivariate analysis revealed 
that VEGFR-3 expression was not an independent fac-
tor influencing lymph node metastasis. In addition, 
VEGFR-3 expression was also detected in tumor cells 
(data not shown). Similar pattern of VEGFR-3 in colo-
rectal cancer was also reported"'. Although the signifi-
cance of such expression is still unclear, it is possible 
that VEGFR-3 plays a role in tumor growth in an 
autocrine manner. Further studies should be performed 
to elucidate the role of VEGFR-3 on tumor cells. 
 In conclusion, we have demonstrated in the present 
study a close relationship between VEGF-D expression 
and lymph node metastasis in colorectal cancer. Our 
study suggests that the detection of VEGF-D protein 
in the primary tumor may represent a potential risk 
of lymph node metastasis in colorectal cancer.
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